{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:13:38Z","timestamp":1773389618976,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) have established cardiorenal benefits in human medicine; however, clinical reports describing their use as a decongestive strategy in cats with congestive heart failure (CHF) complicated by advanced chronic kidney disease (CKD) remain limited. This case describes an 11-year-old neutered male British Shorthair cat with advanced CKD (IRIS stage 3\u20134) that developed CHF manifested by pleural and pericardial effusion. Thoracic radiographs confirmed pleural effusion, and echocardiography identified pericardial effusion with a hypertrophic cardiomyopathy (HCM) phenotype and left atrial enlargement, accompanied by severe azotemia on laboratory testing. Pleural effusion was managed initially with thoracocentesis for respiratory palliation, achieving partial drainage. Because escalation of loop-diuretic therapy was considered undesirable due to concern for worsening renal function, bexagliflozin (5\u202fmg\/cat PO q24h) was initiated with pimobendan as an adjunct\/bridge strategy, and subcutaneous fluids were temporarily withheld given concern for fluid overload. During follow-up, serial thoracic radiographs and echocardiography documented progressive improvement culminating in complete resolution of pleural and pericardial effusions; subcutaneous fluid therapy was reintroduced thereafter without recurrence, and the cat has remained clinically stable. Renal indices fluctuated early but subsequently showed a tendency toward stabilization rather than a progressive worsening trajectory. Structured safety monitoring\u2014including serial assessment of urinary glucose, blood glucose, and ketones\u2014did not reveal clinically significant adverse events. This case suggests that, in carefully selected cats with CHF and advanced CKD in which conventional diuretic escalation is high risk, SGLT2i may be considered as an adjunct\/bridge option for decongestion, with particular emphasis on proactive monitoring for ketone abnormalities and euglycemic ketoacidosis.<\/jats:p>","DOI":"10.3389\/fvets.2026.1791139","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:25:58Z","timestamp":1773379558000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Bexagliflozin as an adjunct decongestive strategy in a cat with congestive heart failure and advanced chronic kidney disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Byung-Jun","family":"Kim","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, Chungnam National University","place":["Daejeon, Republic of Korea"]},{"name":"Hannam Cardiology and Internal Medicine Animal Hospital","place":["Seoul, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Ho","family":"Song","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, Chungnam National University","place":["Daejeon, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2460\/javma.253.2.181","article-title":"Characterization of and factors associated with causes of pleural effusion in cats","volume":"253","author":"Ruiz","year":"2018","journal-title":"J Am Vet Med Assoc"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/j.1939-1676.2007.tb03056.x","article-title":"Pericardial effusion in cats: a retrospective study of clinical findings and outcome in 146 cats","volume":"21","author":"Hall","year":"2007","journal-title":"J Vet Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/jvim.15745","article-title":"ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats","volume":"34","author":"Fuentes","year":"2020","journal-title":"J Vet Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1016\/j.jvc.2015.09.007","article-title":"Management of acute heart failure in cats","volume":"17","author":"Ferasin","year":"2015","journal-title":"J Vet Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e17254","DOI":"10.1111\/jvim.17254","article-title":"Frequency and progression of azotemia during acute and chronic treatment of congestive heart failure in cats","volume":"39","author":"Rogg","year":"2025","journal-title":"J Vet Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/jsap.12387","article-title":"Cardiovascular\u2013renal axis disorders in the domestic dog and cat: a veterinary consensus statement","volume":"56","author":"Pouchelon","year":"2015","journal-title":"J Small Anim Pract"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12933-023-02042-9","article-title":"Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jvp.13472","article-title":"Sodium glucose transporter 2 inhibitors: will these drugs benefit non-diabetic veterinary patients with cardiac and kidney diseases?","author":"Elliott","year":"2024","journal-title":"J Vet Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1480977","DOI":"10.3389\/fvets.2025.1480977","article-title":"Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats","volume":"12","author":"Vieira","year":"2025","journal-title":"Front Vet Sci"},{"key":"ref15","first-page":"52","article-title":"Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus","volume":"86","author":"Benedict","year":"2022","journal-title":"Can J Vet Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1098612X251380011","article-title":"Clinical therapeutics in feline medicine: updates for old and new drugs","volume":"27","author":"Susi","year":"2025","journal-title":"J Feline Med Surg"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.vas.2025.100510","article-title":"Pilot study on the effects of dapagliflozin on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve disease","volume":"30","author":"Saengklub","year":"2025","journal-title":"Vet Anim Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1292\/jvms.25-0040","article-title":"Sodium-glucose co-transporter 2 inhibitors: prospects for canine myxomatous mitral valve disease and finding the \u201cright drug\u201d and the \u201cright dose\u201d for dogs","volume":"87","author":"Umezawa","year":"2025","journal-title":"J Vet Med Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.3390\/ijms22115863","article-title":"Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects","volume":"22","author":"Palmiero","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/FJC.0000000000001380","article-title":"Mechanisms of SGLT2 inhibitors in heart failure and their clinical value","volume":"81","author":"Xie","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/CRD.0000000000000637","article-title":"SGLT2 inhibition in heart failure: clues to cardiac effects?","volume":"33","author":"Savage","year":"2025","journal-title":"Cardiol Rev"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1098612X251386638","article-title":"Use of pimobendan in cats: a practical evidence-based review","volume":"27","author":"Gordon","year":"2025","journal-title":"J Feline Med Surg"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses","volume":"131","author":"Filippatos","year":"2019","journal-title":"Postgrad Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3949\/ccjm.92a.24071","article-title":"Managing the side effects of sodium-glucose cotransporter-2 inhibitors","volume":"92","author":"Kodur","year":"2025","journal-title":"Cleve Clin J Med"},{"key":"ref27","volume-title":"A Compound for the Management of feline Diabetes. World Intellectual Property Organization (WIPO) patent WO2020186142A1","author":"Hadd","year":"2020"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/1040638711428332","article-title":"Measurement of \u03b2-hydroxybutyrate in cats with nonketotic diabetes mellitus, diabetic ketosis, and diabetic ketoacidosis","volume":"24","author":"Weingart","year":"2012","journal-title":"J Vet Diagn Invest"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1791139\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:26:01Z","timestamp":1773379561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1791139\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":28,"alternative-id":["10.3389\/fvets.2026.1791139"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2026.1791139","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"article-number":"1791139"}}